drugset / Trial / NCT02233218

The Pharmacokinetic Drug-drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers

NCT02233218

Phase 1 Completed 60 enrolled Yuhan Corporation
Non-randomizedCrossoverOpen-labelSupportive care

Summary

To investigate the pharmacokinetic Drug-drug interaction

Timeline

Start
2014-07
Primary completion
2014-10
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 10 mg
Subject Rosuvastatin Small molecule 20 mg
Subject Telmisartan Other / unclassified 80 mg

Indications

No indication recorded.